Boehringer Ingelheim today announced the LUME-Colon 1 trial, investigating nintedanib plus best supportive care versus BSC alone, met one of the co-primary endpoints of progression-free survival in pre-treated patients with metastatic colorectal cancer , who no longer responded to or tolerated other available treatments. While nintedanib showed clear anti-tumor activity and significantly reduced the risk of disease progression by 42% versus BSC, this did not translate into an overall survival benefit, the second co-primary endpoint.
